Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands

Cancer Research

Volumn 68, Issue 15, 2008, Pages 6377-6386

  Vlotides, George ^a   Siegel, Emily ^a   Donangelo, Ines ^a   Gutman, Shiri ^a   Ren, Song Guang ^a   Melmed, Shlomo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GROWTH HORMONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROLACTIN; PROTEIN P185; SOMATOMEDIN C; ANTINEOPLASTIC AGENT; LIGAND; PRIMER DNA; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN GH3; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GROWTH HORMONE SECRETING CELL; GROWTH REGULATION; HYPOPHYSIS TUMOR; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROLACTIN SECRETING CELL; PROLACTINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; WEIGHT GAIN; WESTERN BLOTTING; ANIMAL; CELL DIVISION; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA PRIMERS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOPRECIPITATION; LIGANDS; MICE; MICE, NUDE; PITUITARY NEOPLASMS; POLYMERASE CHAIN REACTION; PROLACTINOMA; QUINAZOLINES; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 51049093196     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0508     Document Type: Article

References (50)

1. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 2003;112:1603-18.
2. Melmed S. Medical progress: acromegaly. N Engl J Med 2006;355:2558-73.
3. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485-534.
4. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006;367:1605-17.
5. Shomali ME, Katznelson L. Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary 2002;5:89-98.
6. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006;65:265-73.
7. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005;90:3089-99.
8. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF, Jr., Lloyd RV. Pituitary carcinoma: a clinicopathological review. Neurosurgery 2005;56:1066-74; discussion -74.
9. Zhang H, Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007;117:2051-8.
10. Kontogeorgos G, Stefaneanu L, Kovacs K, Cheng Z. Localization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) in human pituitary adenomas and nontumorous pituitaries: an immunocytochemical study. Endocr Pathol 1996;7:63-70.
11. Botelho CH, Magalhaes AV, Mello PA, Schmitt FC, Casulari LA. Expression of p53, Ki-67 and c-erb B2 in growth hormone- and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr 2006;64:60-6.
12. Roncaroli F, Nose V, Scheithauer BW, et al. Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two cases. J Neurosurg 2003;99:402-8.
13. Onguru O, Scheithauer BW, Kovacs K, et al. Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol 2004;17:772-80.
14. Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer CJ, Melmed S. Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells. Mol Endocrinol 2006;20:3321-35.
15. Vlotides G, Eigler T, Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 2007;28:165-86.
16. Chesnokova V, Auernhammer CJ, Melmed S. Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology 1998;139:2209-16.
17. Zhang X, Horwitz GA, Prezant TR, et al. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1999;13:156-66.
18. Wang Z, Yu R, Melmed S. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol Endocrinol 2001;15:1870-9.
19. Gruszka A, Ren SG, Dong J, Culler MD, Melmed S. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 2007;148:6107-14.
20. Drebin JA, Stern DF, Link VC, Weinberg RA, Greene MI. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984;312:545-8.
21. Dobashi K, Weiner DB, Greene MI. Differential regulation of oncogenic and cellular p185 by serine/ threonine kinases. DNA 1989;8:723-32.
22. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-92.
23. She Y, Lee F, Chen J, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 2003;9:3773-8.
24. Fan X, Childs GV. Epidermal growth factor and transforming growth factor-a messenger ribonucleic acids and their receptors in the rat anterior pituitary: localization and regulation. Endocrinology 1995;136:2284-93.
25. Childs GV, Rougeau D, Unabia G. Corticotropin-releasing hormone and epidermal growth factor: mitogens for anterior pituitary corticotropes. Endocrinology 1995;136:1595-602.
26. Childs GV, Unabia G. Epidermal growth factor and gonadotropin-releasing hormone stimulate proliferation of enriched population of gonadotropes. Endocrinology 2001;142:847-53.
27. Felix R, Meza U, Cota G. Induction of classical lactotropes by epidermal growth factor in rat pituitary cell cultures. Endocrinology 1995;136:939-46.
28. Kakeya T, Takeuchi S, Takahashi S. Epidermal growth factor, insulin, and estrogen stimulate development of prolactin-secreting cells in cultures of GH3 cells. Cell Tissue Res 2000;299:237-43.
29. Roh M, Paterson AJ, Asa SL, Chin E, Kudlow JE. Stage-sensitive blockade of pituitary somatomammotrope development by targeted expression of a dominant negative epidermal growth factor receptor in transgenic mice. Mol Endocrinol 2001;15:600-13.
30. Borgundvaag B, Kudlow JE, Mueller SG, George SR. Dopamine receptor activation inhibits estrogen-stimulated transforming growth factor-α gene expression and growth in anterior pituitary, but not in uterus. Endocrinology 1992;130:3453-8.
31. McAndrew J, Paterson AJ, Asa SL, McCarthy KJ, Kudlow JE. Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 1995;136:4479-88.
32. Theodoropoulou M, Arzberger T, Gruebler Y, et al. Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 2004;183:385-94.
33. Chaidarun SS, Eggo MC, Sheppard MC, Stewart PM. Expression of epidermal growth factor (EGF), its receptor, and related oncoprotein (erbB-2) in human pituitary tumors and response to EGF in vitro. Endocrinology 1994;135:2012-21.
34. Jaffrain-Rea ML, Petrangeli E, Lubrano C, et al. Epidermal growth factor binding sites in human pituitary macroadenomas. J Endocrinol 1998;158:425-33.
35. Wang YH, Jue SF, Maurer RA. Thyrotropin-releasing hormone stimulates phosphorylation of the epidermal growth factor receptor in GH3 pituitary cells. Mol Endocrinol 2000;14:1328-37.
36. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;45:649-57.
37. Serova M, Ghoul A, Benhadji KA, et al. Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol 2006;33:466-78.
38. Pickett CA, Manning N, Akita Y, Gutierrez-Hartmann A. Role of specific protein kinase C isozymes in mediating epidermal growth factor, thyrotropin-releasing hormone, and phorbol ester regulation of the rat prolactin promoter in GH4/GH4C1 pituitary cells. Mol Endocrinol 2002;16:2840-52.
39. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
40. Liang CC, Chen HC. Sustained activation of extracellular signal-regulated kinase stimulated by hepatocyte growth factor leads to integrin α2 expression that is involved in cell scattering. J Biol Chem 2001;276:21146-52.
41. Pouyssegur J, Volmat V, Lenormand P. Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 2002;64:755-63.
42. Stanciu M, DeFranco DB. Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line. J Biol Chem 2002;277:4010-7.
43. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-85.
44. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
45. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
46. Carpenter G. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. J Cell Biol 1999;146:697-702.
47. Gschwind A, Zwick E, Prenzel N, Leserer M, Ullrich A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 2001;20:1594-600.
48. Kovacs K, Horvath E, Syro LV, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 2007;38:185-9.
49. Neff LM, Weil M, Cole A, et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 2007;10:81-6.
50. Goffin V, Touraine P, Culler MD, Kelly PA. Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab 2006;2:571-81.